ATE509621T1 - Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen - Google Patents

Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen

Info

Publication number: ATE509621T1
Authority: AT; Austria
Prior art keywords: pain; treat arthritis; dihydroxybenzene derivatives; dihydroxybenzene; derivatives
Prior art date: 2006-08-16

Application number

AT07788431T

Other languages

English (en)

Inventor

Sanchez Pedro Cuevas

Gallego Guillermo Gimenez

De Tejada Gorman Inigo Saenz

Frutos Javier Angulo

Puerto Rosa Maria Lozano

Garrido Antonio Romero

Lapez Serafin Valverde

Original Assignee

Action Medicines Sl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-16

Filing date

2007-08-15

Publication date

2011-06-15

2006-08-16 Priority claimed from ES200602217A external-priority patent/ES2315117B1/es

2007-08-15 Application filed by Action Medicines Sl filed Critical Action Medicines Sl

2011-06-15 Application granted granted Critical

2011-06-15 Publication of ATE509621T1 publication Critical patent/ATE509621T1/de

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT07788431T 2006-08-16 2007-08-15 Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen ATE509621T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ES200602217A ES2315117B1 (es)	2006-08-16	2006-08-16	Uso de derivados 2,5-dihidroxibencenicos en la preparacion de medicamentos utiles en el tratamiento de asma.
ES200701855		2007-07-02
PCT/EP2007/058446 WO2008020033A1 (en)	2006-08-16	2007-08-15	Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain

Publications (1)

Publication Number	Publication Date
ATE509621T1 true ATE509621T1 (de)	2011-06-15

Family

ID=38515369

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT07788431T ATE509621T1 (de)	2006-08-16	2007-08-15	Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen
AT07788436T ATE510536T1 (de)	2006-08-16	2007-08-15	Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT07788436T ATE510536T1 (de)	2006-08-16	2007-08-15	Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen

Country Status (8)

Country	Link
US (2)	US20080114063A1 (de)
EP (3)	EP2056804B1 (de)
AR (5)	AR062396A1 (de)
AT (2)	ATE509621T1 (de)
CL (5)	CL2007002388A1 (de)
ES (1)	ES2495965T3 (de)
PT (3)	PT2056804E (de)
WO (5)	WO2008020042A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070149618A1 (en)	2004-02-17	2007-06-28	Action Medicines, S.L.	Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
US20080125485A1 (en)	2004-02-17	2008-05-29	Action Medicines	Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
ES2238924B1 (es) *	2004-02-17	2006-12-01	Investread Europa, S.L.	Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
EP2056813B1 (de) *	2006-08-16	2013-07-10	Amderma Pharmaceuticals, Llc	2,5-dihydroxybenzol-verbindungen zur behandlung von rosacea
WO2009103069A1 (en)	2008-02-15	2009-08-20	Osborne David W	Skin penetration enhancing systems for polar drugs
FR2951085B1 (fr) *	2009-10-09	2012-05-18	Inst Substances Vegetales	Utilisation de composes phenoliques pour la deglycation des proteines
ES2385160B1 (es) *	2010-12-23	2013-05-24	Italfármaco, S.A.	Compuestos con actividad inhibitoria de factores de crecimiento de fibroblastos.
ES2632012T3 (es) *	2012-02-02	2017-09-07	Invesfovea S.L.	Uso del ácido 2,5-dihidroxibenceno sulfonato para el tratamiento de la degeneración macular relacionada con la edad
PL404138A1 (pl) *	2013-05-31	2014-12-08	Warszawski Uniwersytet Medyczny	Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα
ES2759080T3 (es) *	2015-10-19	2020-05-07	Dobecure S L	Administración local de etamsilato como medicamento

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4115648A (en) *	1974-09-13	1978-09-19	Laboratorios Del Dr. Esteve, S.A.	2,5-Dihydroxy benzene sulfonic acid mono esters
US4513007A (en) *	1983-05-03	1985-04-23	Laboratoires Om Sa	Method for treating heart disease
US4617311A (en) *	1985-05-17	1986-10-14	Eli Lilly And Company	Antiasthmatic method
CH679372A5 (de) *	1989-04-07	1992-02-14	Vet Gerhard Stuker Dr Med
CH682716A5 (de) *	1992-01-13	1993-11-15	Christian Fricker	Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5981569A (en) *	1992-11-13	1999-11-09	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5374772A (en) *	1992-12-08	1994-12-20	Hoffmann-Laroche Inc.	Substituted benzoic acids, inhibitors of phospholipases A2
US5798356A (en) *	1995-08-07	1998-08-25	Alcon Laboratories, Inc.	Angiostatic compounds
US5977117A (en) *	1996-01-05	1999-11-02	Texas Biotechnology Corporation	Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US6495579B1 (en) *	1996-12-02	2002-12-17	Angiotech Pharmaceuticals, Inc.	Method for treating multiple sclerosis
WO1998035668A1 (fr) *	1997-02-14	1998-08-20	Kissei Pharmaceutical Co., Ltd.	Medicaments entravant l'evolution du pterygion et sa recurrence postoperatoire
US20020103141A1 (en) *	1998-12-23	2002-08-01	Mckearn John P.	Antiangiogenic combination therapy for the treatment of cancer
DE69825495T2 (de) *	1998-12-23	2005-07-28	Idea Ag	Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
JP2000256259A (ja) *	1999-03-11	2000-09-19	Nippon Zoki Pharmaceut Co Ltd	メイラード反応阻害剤
AU5871000A (en) *	1999-06-11	2001-01-02	Paul G. Abrams	High dose radionuclide complexes for bone marrow suppression
US6921763B2 (en) *	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
US20020037897A1 (en) *	2000-08-07	2002-03-28	3-Dimensional Pharmaceuticals, Inc.	Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
JP2002193800A (ja) *	2000-12-22	2002-07-10	Taisho Pharmaceut Co Ltd	Ｖｅｇｆ受容体拮抗剤
JP2004520414A (ja) *	2001-02-28	2004-07-08	メラキュアセラピューティクスエービー	ジヒドロ葉酸レダクターゼ阻害剤として使用するためのジアミノキナゾリンエステル類
EP1452521A4 (de) *	2001-08-17	2007-03-14	Eisai R&D Man Co Ltd	Cyclische verbindung und ppar-agonist
WO2003024452A1 (de) *	2001-09-14	2003-03-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue arzneimittel zur inhalation
US7163958B2 (en) *	2002-07-03	2007-01-16	Nitromed Inc.	Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
RU2002120366A (ru) *	2002-08-01	2005-02-27	БиоДием Лимитед (AU)	Новые производные имидазолия и фармацевтические композиции на их основе
EP1535915A4 (de) *	2002-09-06	2005-10-05	Takeda Pharmaceutical	Furan- oder thiophenderivat und dessen medizinische verwendung
ES2208123A1 (es) *	2002-11-29	2004-06-01	Laboratorios Del Dr. Esteve, S.A.	Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
WO2006066894A1 (en) *	2004-12-24	2006-06-29	Ctg Pharma S.R.L.	Compounds for treating metabolic syndrome
US7595055B2 (en) *	2003-01-29	2009-09-29	Dal-Hoon Son	Pharmaceutical composition comprising an extract or compounds isolated from Elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications
ES2222831B2 (es) *	2003-07-30	2006-02-16	Laboratorios Del Dr. Esteve, S.A.	Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
WO2005013949A2 (en) *	2003-08-07	2005-02-17	Allergan, Inc.	Method for treating cachexia with retinoid ligands
GB0321228D0 (en) *	2003-09-10	2003-10-08	Inpharmatica Ltd	Modulating cell activity
EP1684725A1 (de) *	2003-10-31	2006-08-02	Elan Pharma International Limited	Neue nimesulid-zusammensetzungen
US20050222247A1 (en) *	2003-12-13	2005-10-06	Bayer Healthcare Ag	Chroman derivatives
EP1676573A1 (de) *	2004-12-30	2006-07-05	Laboratorios Del Dr. Esteve, S.A.	Pharmazeutische Zusammensetzung enthaltend eine 2,5-Dihydroxybenzolsulfonsäure-Verbindung, einen Kalium Kanal Modulator und einen Phosphodiesterase 5 Inhibitor
EP1749820A1 (de) *	2005-07-15	2007-02-07	Laboratorios Del Dr. Esteve, S.A.	Salze von substituierten Pyrazolin Derivaten, ihre Herstellung und Anwendung als Arzneimittel
US20080279932A1 (en) *	2005-08-04	2008-11-13	Jean-Louis Reber	Compounds
CN100506804C (zh) *	2006-01-26	2009-07-01	于学敏	羟苯磺酸烷基吡嗪药物及其制备方法和应用
US20070196350A1 (en) *	2006-02-22	2007-08-23	Bartels Stephen P	Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
WO2007113855A1 (en) *	2006-03-30	2007-10-11	Council Of Scientific & Industrial Research	A bioactive fraction from zingiber officinale and a process for the preparation thereof

2007
- 2007-08-15 WO PCT/EP2007/058456 patent/WO2008020042A1/en active Application Filing
- 2007-08-15 PT PT78026168T patent/PT2056804E/pt unknown
- 2007-08-15 WO PCT/EP2007/058444 patent/WO2008020031A1/en active Application Filing
- 2007-08-15 EP EP07802616.8A patent/EP2056804B1/de active Active
- 2007-08-15 PT PT07788436T patent/PT2056805E/pt unknown
- 2007-08-15 ES ES07802616.8T patent/ES2495965T3/es active Active
- 2007-08-15 EP EP07788431A patent/EP2054045B1/de active Active
- 2007-08-15 US US11/839,529 patent/US20080114063A1/en not_active Abandoned
- 2007-08-15 AT AT07788431T patent/ATE509621T1/de not_active IP Right Cessation
- 2007-08-15 WO PCT/EP2007/058445 patent/WO2008020032A1/en active Application Filing
- 2007-08-15 WO PCT/EP2007/058447 patent/WO2008020034A1/en active Application Filing
- 2007-08-15 US US12/377,837 patent/US9060966B2/en not_active Expired - Fee Related
- 2007-08-15 PT PT07788431T patent/PT2054045E/pt unknown
- 2007-08-15 EP EP07788436A patent/EP2056805B1/de active Active
- 2007-08-15 WO PCT/EP2007/058446 patent/WO2008020033A1/en active Application Filing
- 2007-08-15 AT AT07788436T patent/ATE510536T1/de not_active IP Right Cessation
- 2007-08-16 CL CL2007002388A patent/CL2007002388A1/es unknown
- 2007-08-16 AR ARP070103640A patent/AR062396A1/es unknown
- 2007-08-16 CL CL2007002386A patent/CL2007002386A1/es unknown
- 2007-08-16 CL CL2007002385A patent/CL2007002385A1/es unknown
- 2007-08-16 AR ARP070103634A patent/AR062390A1/es unknown
- 2007-08-16 AR ARP070103637A patent/AR062393A1/es unknown
- 2007-08-16 CL CL2007002387A patent/CL2007002387A1/es unknown
- 2007-08-16 AR ARP070103643A patent/AR062399A1/es unknown
- 2007-08-16 CL CL2007002392A patent/CL2007002392A1/es unknown
- 2007-08-16 AR ARP070103639A patent/AR062395A1/es unknown

Also Published As

Publication number	Publication date
WO2008020032A8 (en)	2008-04-17
CL2007002385A1 (es)	2008-01-18
AR062396A1 (es)	2008-11-05
PT2054045E (pt)	2011-08-31
CL2007002392A1 (es)	2008-01-18
AR062393A1 (es)	2008-11-05
EP2056804A1 (de)	2009-05-13
PT2056804E (pt)	2014-07-11
AR062399A1 (es)	2008-11-05
WO2008020033A1 (en)	2008-02-21
CL2007002387A1 (es)	2008-01-18
US20110152222A1 (en)	2011-06-23
WO2008020034A1 (en)	2008-02-21
EP2056805B1 (de)	2011-05-25
WO2008020031A1 (en)	2008-02-21
US20080114063A1 (en)	2008-05-15
EP2056804B1 (de)	2013-05-22
AR062395A1 (es)	2008-11-05
EP2054045A1 (de)	2009-05-06
EP2054045B1 (de)	2011-05-18
CL2007002386A1 (es)	2008-01-18
ES2495965T3 (es)	2014-09-17
EP2056805A1 (de)	2009-05-13
CL2007002388A1 (es)	2008-01-18
US9060966B2 (en)	2015-06-23
PT2056805E (pt)	2011-09-02
WO2008020032A1 (en)	2008-02-21
WO2008020042A1 (en)	2008-02-21
AR062390A1 (es)	2008-11-05
ATE510536T1 (de)	2011-06-15

Publication	Publication Date	Title
ATE509621T1 (de)	2011-06-15	Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen
ATE534379T1 (de)	2011-12-15	Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen
ATE490825T1 (de)	2010-12-15	Behandlung von mineralschlämmen mit verbesserter pflanzenwachstumsrehabilitation
DE602006006354D1 (de)	2009-06-04	Pinolensäure zur Behandlung von Übergewicht
ATE512948T1 (de)	2011-07-15	Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
ATE521352T1 (de)	2011-09-15	Verwendung von flibanserin zur behandlung von prämenopausalen störungen der sexuellen lust
ATE495179T1 (de)	2011-01-15	Tetrahydropyridothienpyrimidin-verbindungen und verwendung zur behandlung proliferativer erkrankungen
DE602007011908D1 (de)	2011-02-24	Verwendung von gpr119-rezeptoragonisten zur vermehrung der knochenmasse und zur behandlung von osteoporose sowie kombinationstherapie dafür
DE602005009748D1 (de)	2008-10-23	3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
ATE434620T1 (de)	2009-07-15	Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE534633T1 (de)	2011-12-15	Indazolderivate zur behandlung von hsp90- induzierten krankheiten
DE60234873D1 (de)	2010-02-04	Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen
ATE483460T1 (de)	2010-10-15	Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE438623T1 (de)	2009-08-15	Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
DE502005010499D1 (de)	2010-12-23	Implantat zur Behandlung von Fettsucht
DE602006007323D1 (de)	2009-07-30	VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
ATE504297T1 (de)	2011-04-15	Visnadin zur behandlung von kopfhautjucken
DE602007009877D1 (de)	2010-11-25	Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
DE602004022035D1 (de)	2009-08-27	Verwendung von pthalide derivativen zur behandlung
DE602005015297D1 (de)	2009-08-20	Verwendung von ozon zur verbesserung des knetvorgangs
DE602005016141D1 (de)	2009-10-01	S-mirtazapin zur behandlung von hitzewallungen
ATE534392T1 (de)	2011-12-15	Verwendung eines neuen therapeutikums zur behandlung von leukämie
ATE489947T1 (de)	2010-12-15	Axomadol zur schmerzbehandlung bei arthrose
DE602006010364D1 (de)	2009-12-24	Pharmazeutikum zur prävention oder behandlung von metabolischer knochenkrankheit
ATE376416T1 (de)	2007-11-15	Verwendung von ambroxol zur behandlung von chronischen schmerzen

Legal Events

Date	Code	Title	Description
2011-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties